Dae-Woong Cho
Directeur Général chez CELLIVERY THERAPEUTICS, INC.
Fortune : 26 M $ au 31/03/2023
Profil
Dae-Woong Cho was the founder of ProCell Therapeutics, Inc. (founded in 2005) where he held the title of President & Chief Executive Officer from 2010 to 2012.
He is also the founder of Cellivery Therapeutics, Inc. (founded in 2014) where he currently holds the titles of CEO, Director & Research Director.
Dr. Cho's former job(s) include working as a Principal at Vanderbilt University, Yuhan Corp., GenoCheck Co., Ltd., and Chonnam National University.
Dr. Cho's education history includes a doctorate degree from Vanderbilt University in 2005 and a graduate degree from Hanyang University in 1992.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CELLIVERY THERAPEUTICS, INC.
13,40% | 30/06/2023 | 4 899 454 ( 13,40% ) | 26 M $ | 31/03/2023 |
Postes actifs de Dae-Woong Cho
| Sociétés | Poste | Début |
|---|---|---|
| CELLIVERY THERAPEUTICS, INC. | Directeur Général | 28/08/2014 |
Anciens postes connus de Dae-Woong Cho
| Sociétés | Poste | Fin |
|---|---|---|
ProCell Therapeutics, Inc.
 ProCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ProCell Therapeutics, Inc. develops protein-based therapeutics. It handles the research and development of biotherapeutics capable of entering cells through proprietary Macromolecule Intracellcellular Transduction Technologies (MITT) using a line-up of Macromolecule Transduction Domain (MTD). The company was founded on December 12, 2005 and is headquartered in Seoul, South Korea. | Fondateur | - |
| Chonnam National University | Corporate Officer/Principal | - |
| YUHAN CORPORATION | Corporate Officer/Principal | - |
GenoCheck Co., Ltd.
 GenoCheck Co., Ltd. Medical SpecialtiesHealth Technology GenoCheck Co., Ltd. is a holding company, which conducts research in biotechnology and offers products and services related to genes. Its activities include exploring and testing of genes related to human diseases, developing diagnostic deoxyribonucleic acid (DNA) chip and new drugs. The firm's products include microarray, ribonucleic acid stabilization solution, and DNA extraction kit. The company was founded on May 1, 2000 and is headquartered in Seoul, South Korea. | Corporate Officer/Principal | - |
| Vanderbilt University | Corporate Officer/Principal | - |
Formation de Dae-Woong Cho
| Vanderbilt University | Doctorate Degree |
| Hanyang University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CELLIVERY THERAPEUTICS, INC. | Health Technology |
| YUHAN CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
GenoCheck Co., Ltd.
GenoCheck Co., Ltd. Medical SpecialtiesHealth Technology GenoCheck Co., Ltd. is a holding company, which conducts research in biotechnology and offers products and services related to genes. Its activities include exploring and testing of genes related to human diseases, developing diagnostic deoxyribonucleic acid (DNA) chip and new drugs. The firm's products include microarray, ribonucleic acid stabilization solution, and DNA extraction kit. The company was founded on May 1, 2000 and is headquartered in Seoul, South Korea. | Health Technology |
ProCell Therapeutics, Inc.
ProCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ProCell Therapeutics, Inc. develops protein-based therapeutics. It handles the research and development of biotherapeutics capable of entering cells through proprietary Macromolecule Intracellcellular Transduction Technologies (MITT) using a line-up of Macromolecule Transduction Domain (MTD). The company was founded on December 12, 2005 and is headquartered in Seoul, South Korea. | Health Technology |
